The 7th annual Retail Clinician Education Congress was held from May 12 to 15, and the program lineup was outstanding this year. From clinical sessions featuring healthcare experts in the industry, such as Alan Agins and Wendy Wright, to executive and leadership sessions featuring Dan Gilman from the Federal Trade Commission and Debra Richman from Harris Interactive, conference attendees had an enriching and educational experience.
The National Association of Chain Drug Stores and a national coalition working to achieve “provider status” for pharmacists under Medicare Part B have asked the Federal Trade Commission to back legislation to this effect, as well as other policies that would help pharmacists practice at the top of their education level, NACDS reported Thursday.
Actavis and Forest Laboratories on Thursday announced that they have each received a request for additional information from the Federal Trade Commission in connection with Actavis' pending acquisition of Forest.
The Electronic Retailing Self-Regulation Program on Tuesday announced it will refer direct response advertising for Dinamo to the Federal Trade Commission and the Food and Drug Administration after the marketer, Natures Flava, failed to respond to an ERSP inquiry.
The Federal Trade Commission is holding a public workshop in March to examine U.S. healthcare competition issues as healthcare spending swallows up a significant part of federal and state budgets. Among the topics up for discussion, according to reports, are retail clinics and telemedicine.
The American Association of Nurse Practitioners, a national professional membership organization for nurse practitioners of all specialties, is calling on state lawmakers to consider the consequences of undue restrictions on APRNs, or nurse practitioners, as recommended by the Federal Trade Commission.
Although the United States is still waiting for final practical guidelines from the Food and Drug Administration about the launch of biosimilars and the standards required to meet the threshold of interchangeability, the rest of the world seems to be barreling forward with the development and launch of these important medicines.
Bi-Lo Holdings and Delhaize Group on Tuesday announced they have received approval from the Federal Trade Commission to proceed with the transaction in which Bi-Lo Holdings will acquire substantially all of the stores in the Sweetbay, Harveys and Reid’s supermarket chains from Delhaize.
The National Advertising Division has referred to the Federal Trade Commission advertising claims made by Brain Research Labs, for Procera AVH, following the company’s failure to abide by the terms of an NAD decision.
Kroger and Harris Teeter Supermarkets on Friday announced that the Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to the pending merger transaction between the two companies.
The Federal Trade Commission announced a law enforcement initiative stopping national marketers that used deceptive advertising claims to peddle fad weight-loss products, from food additives and skin cream to dietary supplements.
NEW YORK — The National Advertising Division has referred advertising claims made by Maxam Nutraceuticals for its PCA dietary supplement to the Federal Trade Commission for further review, after the company declined to participate in a review of its claims.
The Council for Responsible Nutrition challenged claims made by Maxam in television and Internet advertising, including:
The Supreme Court usually has a lot on its plate in any given year, but this year's term included a pretty big case for the pharmaceutical industry: the Federal Trade Commission v. Actavis, which concerned legal settlements between branded and generic drug makers that often occur when the latter attempts to market a generic drug before the former's patents have expired.
Actavis and Warner Chilcott announced that they have each received a request for additional information from the Federal Trade Commission in connection with Actavis' pending acquisition of Warner Chilcott.
Half a loaf, the saying goes, is better than none. For the generic drug industry, that means that the Supreme Court handed it a partial victory Monday by ruling that “pay for delay” patent settlements between brand name and generic drug companies aren’t necessarily illegal and should be considered on a case-by-case, “rule of reason” approach by the Federal Trade Commission, which staunchly opposes the practice.